Aegerion Pharmaceuticals, Inc.(NASDAQ : AEGR)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||1.22%||159.01||0.7%||$1293.99m|
|MRK||Merck & Co., Inc.||-1.04%||73.12||0.7%||$1148.48m|
|BMY||Bristol-Myers Squibb Co.||2.02%||56.53||1.0%||$760.26m|
|LLY||Eli Lilly & Co.||-1.03%||245.33||1.1%||$728.22m|
|DRNA||Dicerna Pharmaceuticals, Inc.||-0.12%||38.08||0.3%||$144.50m|
|RPRX||Royalty Pharma Plc||-2.66%||37.85||0.1%||$111.79m|
|PTPI||Petros Pharmaceuticals, Inc.||4.25%||2.70||0.0%||$93.99m|
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics/pharmaceuticals to treat cardiovascular and metabolic diseases. It develops lomitapide/AEGR-733, a microsomal triglyceride transfer protein inhibitor small molecule drug for decreasing serum lipids, including cholesterol and triglycerides, as well as to treat atherosclerosis, dyslipidemia, obesity, and pancreatitis. The company also focuses on products for the evaluation and treatment of hyperlipidemia. Aegerion Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Bridgewater, New Jersey.